Pharma giants AstraZeneca and GSK , the U.K.'s second and ninth most valuable companies, both saw first-quarter profits beat expectations early Wednesday. AstraZeneca's core earnings per share came in at $2.58, while analysts polled by FactSet had expected $2.53. GSK's core EPS was £0.47 ($0.63) versus the expected £0.43, as per FactSet. It comes as an increasing number of pharma CEOs have warned that Europe could see fewer new drugs launched amid a push by U.S. President Donald Trump to lower prices for medicines in America — unless Europe addresses some of the continent's most pressing issues impacting competitiveness. The CEOs of Novartis, AstraZeneca, Roche , and Boehringer Ingelheim have said that European countries risk missing out on novel medicines, if prices in the lucrative U.S. market are tied to lower prices in comparable countries in Trump's most-favored-nation (MFN) drug pricing policy.…